In December Prime Minister David Cameron outlined his plan to turn the United Kingdom into a world-leader in medical genomics, but beyond the headline grabbing numbers--$160 million to sequence 100,000 whole genomes--details were scarce. Now, the group tasked with the project has spoken up.
The deep divisions in U.S. politics have been more apparent than ever this week, but there was also evidence everyone can pull together. Both Houses of Congress and political parties got behind a bill to set a 10-year deadline for a track-and-trace system that has database implications for drugmakers.
The government shutdown and subsequent furloughing of staff at the National Institutes of Health (NIH) has some obvious, headline-grabbing implications for its trials and research. Yet there are also a host of knock-on effects rippling through the private sector, harming bioinformatics and other fields.
The growing pool of genomics data and bioinformatics capabilities present new opportunities to improve outcomes for cancer patients. Yet without coordinated, multidisciplinary collaborations, the industry risks failing to take full advantage, researchers warned this week.
he tool is freely available, but BioDigital is developing a paid for version, in part to allow biopharma to show the effect their products have on the body.
Over the past decade National Institutes of Health (NIH) has shaped its data-sharing policies to achieve two goals--maximize the value of research, and protect patient privacy and intellectual property. Now, NIH is seeking feedback on its plans to apply these aims to the sharing of genomics data.
The boom in next-generation sequencing (NGS) has given researchers a huge number of providers from which to choose. Yet without the ability to compare the price, reputation and capabilities of all providers, researchers risk wasting cash on subpar services. Genohub aims to fill this knowledge gap.
The upshot of the guidance is most app makers can continue to push out their products without worrying about FDA regulation. FDA will only step in when apps stray into areas that convert mobile devices into tools the agency traditionally regulates as medical devices.
The use of existing drugs in new therapeutic areas has a rich history, with Viagra's serendipitous pivot from anti-angina flop to erectile dysfunction blockbuster being the standout example. Bioinformatics is now taking the guesswork out of repositioning, slashing the time and money needed to reach the clinic.
Patients who have participated in Pfizer clinical trials will be able to download their data using the 'Blue Button' standard introduced by the White House.
When the FDA published draft guidance on electronic source data in clinical trials back in January 2012, it sparked a widespread debate, some of which was critical of the proposals. Now, after a reworked draft was received more favorably by the industry, the administration has published its final guidance on the topic.
A financial watchdog has fined a broker $5,000 for comments he made about Arena Pharmaceuticals on Facebook.
When President Obama unveiled the BRAIN Initiative in April, his speech was heavy on lofty rhetoric but light on detail. This week the team tasked with turning the grand vision into practical projects filed its first report, and placed strong emphasis on improving data storage, analysis and interpretation.
Google has played on the fringes of healthcare for years, investing in 23andMe, DNAnexus and other bio startups through its venture capital unit. Now it has set up its own biotech, outlined vague but wildly-ambitious goals, and hired ex-Genentech CEO Art Levinson to lead the company.
Eisai subsidiary H3 Biomedicine has drummed up lots of interest in its bioinformatics-driven approach to cancer therapies since setting up shop in Massachusetts in 2011. The latest to talk up the strategy is Polish biotech Selvita, which has teamed up with H3 to investigate several kinase targets.
The New York Genome Center (NYGC) has always had big ambitions, but over its three-year history has lacked a physical presence to match its aspirations.
Big Pharma and academic groups have made more progress in joining forces on advancing software for translational research on a pre-competitive basis.
Qlucore, a provider of scientific software, has won €600,000 ($801,360) over three years from the European Commission's 7th Framework Program to develop algorithms for use in personalizing treatment of hepatitis C virus.
Clinicians have found help from a new mobile app to gauge risks of coronary events in patients with heart disease, guiding them in designing treatment plans.
The Center for Brains, Minds and Machines, based in Cambridge, MA, is one of three new centers to win funding from the NSF's Science and Technology Centers Integrative Partnerships.